Market Place
Sourcing Support
Neurocrine Buys Soleno at Discount as Europe Prospects Fade
21 Apr 2026 //
ENDPOINTS NEWS
Neurocrine Biosciences Announces Q1 2026 Earnings Call, Webcast
15 Apr 2026 //
PR NEWSWIRE
Neurocrine Biosciences Shows INGREZZA Outperforms AUSTEDO XR
14 Apr 2026 //
PR NEWSWIRE
Neurocrine Biosciences Presents on Tardive Dyskinesia
26 Mar 2026 //
PR NEWSWIRE
Neurocrine Biosciences Names Ratz Chief Technical Ops Officer
18 Mar 2026 //
PR NEWSWIRE
Neurocrine Biosciences To Present At Stifel 2026 CNS Forum
10 Mar 2026 //
PR NEWSWIRE BIO
Neurocrine Biosciences To Present At March Investor Conferences
24 Feb 2026 //
PR NEWSWIRE
Neurocrine Biosciences Announces Q4 2025 Earnings
21 Jan 2026 //
PR NEWSWIRE
Neurocrine Biosciences at 44th J.P. Morgan Healthcare Conference
05 Jan 2026 //
PR NEWSWIRE
Neurocrine`s Movement Disorder Treatment Fails Late-Stage Trial
23 Dec 2025 //
BIOSPACE
Neurocrine Biosciences To Host R&D Day On December 16
10 Dec 2025 //
PR NEWSWIRE
Neurocrine`s Review Contrasts Tardive Dyskinesia Drugs
23 Nov 2025 //
INDPHARMAPOST
Neurocrine Biosciences To Present At Investor Conferences
12 Nov 2025 //
PR NEWSWIRE
Neurocrine Biosciences Releases Q3 2025 Financial Results
29 Oct 2025 //
PR NEWSWIRE
Neurocrine Biosciences To Host Conference Call For Q3 2025
07 Oct 2025 //
PR NEWSWIRE
Neurocrine Reports Positive Ph 2 Osavampator Data In MDD
22 Sep 2025 //
PR NEWSWIRE
Neurocrine Biosciences to Present at Investor Conferences
26 Aug 2025 //
PR NEWSWIRE
Neurocrine Biosciences` Q2 2025 Financial Results Released
30 Jul 2025 //
PR NEWSWIRE
Neurocrine Reveals CAHtalog® Data at ENDO 2025
15 Jul 2025 //
PR NEWSWIRE
Neurocrine Shares CAHtalyst™ 1-Year Data at ENDO 2025
14 Jul 2025 //
PR NEWSWIRE
Neurocrine Biosciences Schedules Q2 2025 Financial Results Call
09 Jul 2025 //
PR NEWSWIRE
Neurocrine Reports Ingrezza HRQoL Gains in TD Patients
20 Jun 2025 //
PR NEWSWIRE
Neurocrine Shows INGREZZA Improved QoL In Tardive Dyskinesia
02 Jun 2025 //
PR NEWSWIRE
Neurocrine Shares Ph 2 of NBI-1117568 Data On Schizophrenia Drug
28 May 2025 //
PR NEWSWIRE
Neurocrine Biosciences Presents Positive Data on NBI-1117568
28 May 2025 //
GLOBENEWSWIRE
Neurocrine Shares Data On Steroid Impact In Adrenal Disease
14 May 2025 //
PR NEWSWIRE
Neurocrine, Carnie Wilson Launch TD Awareness Campaign
06 May 2025 //
PR NEWSWIRE
Neurocrine taps Wilson Phillips star for tardive dyskinesia push
06 May 2025 //
FIERCE PHARMA
Neurocrine: TD Survey Shows Need for Earlier Diagnosis
05 May 2025 //
PR NEWSWIRE
Neurocrine Bioscience Reports Q1 2025 Results, Reaffirms Guidance
05 May 2025 //
PR NEWSWIRE
Nxera Pharma`s Partner Neurocrine Biosciences Starts Ph 3 Program
30 Apr 2025 //
GLOBENEWSWIRE
Neurocrine Bio Starts Phase 3 for NBI-1117568 in Schizophrenia
30 Apr 2025 //
PR NEWSWIRE
Neurocrine Bio Study Shows Ingrezza Efficacy in Older Adults
24 Apr 2025 //
PR NEWSWIRE
Neurocrine Biosciences Names Sanjay Keswani Chief Medical Officer
04 Apr 2025 //
CONTRACTPHARMA
Neurocrine Biosciences Presents Real-World Data on VMAT2 Inhibitors
31 Mar 2025 //
PR NEWSWIRE
Neurocrine Bio to Present at Investor Conferences in March
25 Feb 2025 //
PR NEWSWIRE
Neurocrine Board Approves $500M Share Repurchase Program
21 Feb 2025 //
PR NEWSWIRE
Neurocrine Biosciences Reports Q4 & Fiscal 2024 Financial Results
06 Feb 2025 //
PR NEWSWIRE
Neurocrine Sets Q4, Year-End 2024 Results Call, Webcast
30 Jan 2025 //
PR NEWSWIRE
Neurocrine Starts Phase 3 for Osavampator in Major Depressive Disorder
28 Jan 2025 //
PR NEWSWIRE
Neurocrine Biosciences Amends Osavampator Collaboration with Takeda
27 Jan 2025 //
PR NEWSWIRE
Neurocrine Bio Appoint SVP of Drug Development, Delivery & Device
24 Jan 2025 //
CONTRACTPHARMA
Neurocrine Bio to Present at 43rd Annual J.P. Morgan Conference
06 Jan 2025 //
PR NEWSWIRE
Neurocrine Bio Announces Crenessity Availability for CAH Patients
20 Dec 2024 //
PR NEWSWIRE
Neurocrine Presents New KINECT®-HD Data on INGREZZA®
07 Nov 2024 //
PR NEWSWIRE
Neurocrine Biosciences to Participate in November Investor Conf
05 Nov 2024 //
PR NEWSWIRE
Neurocrine Presents INGREZZA® Data at Psych Congress 2024
04 Nov 2024 //
PR NEWSWIRE
Neurocrine Presents Data on INGREZZA® for Tardive Dyskinesia
04 Nov 2024 //
PR NEWSWIRE
Neurocrine Reports Q3 2024 Results, Raises INGREZZA Sales Guidance
30 Oct 2024 //
PR NEWSWIRE
Neurocrine Biosciences Announces Q3 2024 Financial Results Call
09 Oct 2024 //
PR NEWSWIRE
Neurocrine Presents Data On Chorea Improvements In Huntington`s
30 Sep 2024 //
PR NEWSWIRE
Neurocrine halts development of schizophrenia drug as trial fails
12 Sep 2024 //
REUTERS
Nxera To Receive $35M From Neurocrine Upon Positive Phase 2 Schizophrenia Data
01 Sep 2024 //
GLOBENEWSWIRE
Neurocrine`s drug cuts schizophrenia symptoms in mid-stage study
29 Aug 2024 //
REUTERS
Neurocrine Biosciences to Participate at Investor Conferences in September
28 Aug 2024 //
PR NEWSWIRE
Nxera Pharma Reports Q2 And H1 2024 Results And Highlights
09 Aug 2024 //
GLOBENEWSWIRE
Neurocrine Biosciences To Present At Canaccord Genuity Conference
07 Aug 2024 //
PR NEWSWIRE
Neurocrine Launches INGREZZA® SPRINKLE For Easier Administration
18 Jul 2024 //
PR NEWSWIRE
Neurocrine Biosciences To Report Q2 2024 Results Via Conference Call
11 Jul 2024 //
PR NEWSWIRE
FDA Grants Priority Review For Neurocrine`s Crinecerfont In CAH
01 Jul 2024 //
PR NEWSWIRE
